Illumina, Inc. (NASDAQ:ILMN) Stake Reduced by Wellington Shields Capital Management LLC

Wellington Shields Capital Management LLC trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 40,357 shares of the life sciences company’s stock after selling 3,290 shares during the quarter. Illumina comprises about 2.5% of Wellington Shields Capital Management LLC’s holdings, making the stock its 3rd biggest holding. Wellington Shields Capital Management LLC’s holdings in Illumina were worth $14,857,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in ILMN. Copper Rock Capital Partners LLC bought a new position in shares of Illumina in the 2nd quarter worth approximately $10,888,000. Handelsbanken Fonder AB lifted its stake in shares of Illumina by 45.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 60,653 shares of the life sciences company’s stock worth $22,329,000 after purchasing an additional 19,000 shares during the period. Shell Asset Management Co. lifted its stake in shares of Illumina by 5.8% in the 1st quarter. Shell Asset Management Co. now owns 24,863 shares of the life sciences company’s stock worth $7,725,000 after purchasing an additional 1,369 shares during the period. Diversified Trust Co bought a new position in shares of Illumina in the 1st quarter worth approximately $1,544,000. Finally, Hartford Investment Management Co. lifted its stake in shares of Illumina by 0.8% in the 2nd quarter. Hartford Investment Management Co. now owns 18,141 shares of the life sciences company’s stock worth $6,679,000 after purchasing an additional 148 shares during the period. 92.09% of the stock is currently owned by institutional investors.

In other news, SVP Charles Dadswell sold 1,220 shares of Illumina stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $309.70, for a total transaction of $377,834.00. Following the sale, the senior vice president now owns 8,006 shares in the company, valued at $2,479,458.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $349.28, for a total transaction of $3,492,800.00. Following the sale, the senior vice president now owns 65,994 shares in the company, valued at approximately $23,050,384.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,458 shares of company stock worth $19,329,754. Company insiders own 0.38% of the company’s stock.

NASDAQ ILMN traded up $3.05 on Thursday, reaching $284.67. 20,635 shares of the stock were exchanged, compared to its average volume of 987,555. Illumina, Inc. has a one year low of $268.62 and a one year high of $380.76. The firm has a market capitalization of $41.50 billion, a PE ratio of 49.66, a PEG ratio of 2.63 and a beta of 1.10. The company’s 50-day simple moving average is $297.06 and its two-hundred day simple moving average is $315.15. The company has a current ratio of 6.79, a quick ratio of 6.10 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.03. The firm had revenue of $838.00 million for the quarter, compared to analysts’ expectations of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The company’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.43 earnings per share. Sell-side analysts forecast that Illumina, Inc. will post 6.04 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on the stock. ValuEngine upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Piper Jaffray Companies lowered their price objective on shares of Illumina from $382.00 to $348.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 30th. Cowen lowered their price objective on shares of Illumina from $380.00 to $320.00 and set an “outperform” rating on the stock in a research note on Friday, July 12th. Wolfe Research assumed coverage on shares of Illumina in a research note on Thursday, May 30th. They issued an “outperform” rating on the stock. Finally, Deutsche Bank lowered their price objective on shares of Illumina from $290.00 to $280.00 and set a “hold” rating on the stock in a research note on Friday, July 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $330.92.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Story: Strike Price

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.